It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

Fluarix Tetra (GSK) is no longer marketed, while there is no stock of SKYCellflu (Pharmaniaga Marketing, SK Bioscience Korea) in the country, he added. “Currently, there is an unexpected surge ...

The mRNA-1083 generated an equivalent or better immunological response compared to current flu vaccines, matching GSK’s Fluarix Quadrivalent in adults aged 50 to 64 and outperforming Sanofi’s ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co ...

“Fluarix Tetra (GSK) is no longer marketed, and SKYCellflu (Pharmaniaga Marketing, SK Bioscience Korea) has no stock in the country. “Currently, there is an unexpected surge in demand for ...

Fluarix™, GlaxoSmithKline Vaccines) in primed and unprimed cohorts of children aged from 18 to 47 months. The main aim of the study was to assess the non-inferiority of HI antibody responses ...

A second group of adults aged 50 to 64 received mRNA-1083 or GSK’s influenza vaccine Fluarix, once again given alongside Spikevax. mRNA-1083 consists of components of mRNA-1010, Moderna’s ...

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...